PAO Group Inc. (PAOG)

CBD Formulation From Patented Extraction Process

PAO Group, Inc. (PAOG) is proud to now introduce its CBD formulation years in the making for the treatment of symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. The formulation for the treatment of symptoms associated with COPD and other similar respiratory conditions has been derived from a patented cannabis extraction process. In conjunction with the research already conducted and the next phase of research now moving forward, a new patent application has been filed specifically on the CPD formulation for symptoms associated with COPD and other similar respiratory conditions. A trademark on the name RespRx as the brand name for the CBD formulation to treat the symptoms associated with COPD and other similar respiratory conditions has also been filed.
 

More than 65 million people around the world have moderate or severe COPD, and experts predict that this number will continue to rise worldwide over the next 50 years.

Across the eight major economic markets of the US, France, Germany, Italy, Spain, the UK, Japan, and Australia, the COPD treatment market is anticipated to rise from $9.9 billion in 2015 to around $14.1 billion by 2025.